Bronchioloalveolar carcinoma and the significance of invasion predicting biologic behavior

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 10, 2010, Pages 1450-1454

  Schmidt, Lindsay ^a   Myers, Jeffrey ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOPSY; CANCER INVASION; CANCER STAGING; CLASSIFICATION; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LUNG ALVEOLUS; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; METHODOLOGY; PATHOLOGY; PLEURA; PREDICTION AND FORECASTING; PROGNOSIS; RADIOGRAPHY;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; BIOPSY; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLEURA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY ALVEOLI; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77958554992     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Colby T, Noguchi M, Henschke C, et al. Adenocarcinoma. In: Travis W, Brambilla E, Muller-Hermelink H, Harris C, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004: 35-44.
2. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32(6):810-827.
3. Borczuk AC, Qian F, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol. 2009; 33(3):462-469.
4. Garfield D, Cadranel J, West H. Bronchioloalveolar carcinoma: the case for two diseases. Clin Lung Cancer. 2008;9(1):24-29.
5. Yousem SA, Beasley MB. Bronchioloalveolar carcinoma: a review of current concepts and evolving issues. Arch Pathol Lab Med. 2007;131(7):1027-1032.
6. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol. 2001;116(3):319-325.
7. Saad RS, Cho P, Silverman JF, Liu Y. Usefulness of Cd×2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol. 2004;122(3):421-427.
8. Wislez M, Antoine M, Baudrin L, et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer. 2010; 68(2):185-191.
9. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlateswith absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 2007;9(3):320-326.
10. Sakuma Y, Matsukuma S, Yoshihara M, et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol. 2007;128(1):100-108.
11. Breathnach OS, Ishibe N, Williams J, Linnoila RI, Caporaso N, Johnson BE. Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer. 1999;86(7):1165-1173.
12. Varlotto JM, Flickinger JC, Recht A, Nikolov MC, DeCamp MM. A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer: implications for adjuvant therapy. Cancer. 2008;112(7):1547-1554.
13. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg. 2002;74(5):1640-1646.
14. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer. 1995;75(12):2844-2852.
15. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004;28(2):198-206.
16. Yim J, Zhu LC, Chiriboga L, Watson HN, Goldberg JD, Moreira AL. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol. 2007;20(2):233-241.
17. Sakao Y, Miyamoto H, Sakuraba M, et al. Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components. Ann Thorac Surg. 2007;83(1): 209-214.
18. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S, Ochiai A. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000;29(3):179-188.
19. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003;27(7):937-951.
20. Goto K, Yokose T, Kodama T, et al. Detection of early invasion on the basis of basement membrane destruction in small adenocarcinomas of the lung and its clinical implications. Mod Pathol. 2001;14(12):1237-1245.
21. Arenberg D; American College of Chest Physicians. Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 suppl):306S-313S.
22. Nakamura H, Saji H, Ogata A, Saijo T, Okada S, Kato H. Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge resection. Lung Cancer. 2004;44(1):61-68.
23. Koike T, Togashi K, Shirato T, et al. Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination. Ann Thorac Surg. 2009;88(4):1106-1111.
24. Gupta R, McKenna R Jr, Marchevsky AM. Lessons learned from mistakes and deferrals in the frozen section diagnosis of bronchioloalveolar carcinoma and well-differentiated pulmonary adenocarcinoma: an evidence-based pathology approach. Am J Clin Pathol. 2008;130(1):11-20.
25. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15(16):5267-5273.